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Abstract: Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50%
of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in
the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase
level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95%
Confidence Interval (CI) 5.63–14.35), and the presence of liver metastases is negatively associated with
survival (HR 2.09, 95%CI 1.07–4.08). We used data from the nation-wide Dutch Melanoma Treatment
Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV
disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain
metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in
28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of
treatment options, metastatic UM patients are often directed to clinical trials. Patients participating
in clinical trials are often subject to selection and usually do not represent the entire metastatic UM
population. By using our nation-wide cohort, we are able to describe real-life treatment choices made
in metastatic UM patients and 1-year survival rates in selected groups of patients.
Keywords: uveal melanoma; metastatic uveal melanoma; survival; treatment strategy; prognostic
factor
1. Introduction
Uveal melanoma (UM) is the most common primary intraocular tumor in adults and arises from
the melanocytes residing in the stroma [1,2]. Between 2012 and 2018, the incidence of primary uveal
melanoma was approximately 200 new cases per year in the Netherlands [3]. European data on the
incidence of primary uveal melanoma report 4.4 cases per million in Europe [4]. Among all intraocular
melanomas, choroidal melanomas occur most frequently (80–90% of cases), but tumors may also
develop in the iris or ciliary body [2]. The diagnosis of uveal melanoma is based on non-invasive testing
techniques, such as fundoscopy or ultrasound, performed by an experienced clinician. Ocular treatment
of uveal melanoma consists of enucleation (“radical treatment”) or radiotherapy, usually in the form of
plaque brachytherapy or proton radiotherapy (“conservative treatment”) [5]. Management of primary
uveal melanoma is guided by the size and location of the tumor, presence of extraocular extension,
visual potential and patient age and preference. In selected patients, both treatment modalities show
similar survival and risk of metastases, with radiotherapy having the advantage of a better cosmetic
result and the possibility of saving vision in the smaller tumors [6].
Unfortunately, up to 50% of patients with uveal melanoma will ultimately develop metastatic
disease. The most frequently affected metastatic site is the liver [4,6,7]. The site of the metastases has an
impact on survival; patients with liver metastasis have a poorer prognosis than patients with extrahepatic
metastasis [8,9]. Previously, it was thought that there would be no survival advantage in early diagnosis
of metastatic disease because of the lack of standard-of-care therapy for metastatic uveal melanoma.
However, patients with early diagnosis of metastatic disease might benefit from liver-directed therapy,
which is associated with clinical utility [10–15] or they might benefit from participation in a clinical trial.
Under the Dutch and UK uveal melanoma guidelines [16,17], patients with primary uveal melanoma
are therefore advised to have 6-monthly liver function tests in combination with liver-specific imaging
by a non-ionizing modality to detect metastatic disease in an earlier phase.
On a molecular level, uveal melanomas differ significantly from cutaneous melanomas. Unlike
cutaneous melanoma, uveal melanoma is not characterised by frequent BRAF or NRAS mutations,
so that advances in targeted therapy for cutaneous melanoma are not applicable to metastatic uveal
melanoma. Early activating mutations in GNAQ or GNA11 are present in about 80% of primary uveal
melanomas. These lead to activation of downstream signalling pathways. [18] Inactivating somatic
mutations are present in the gene encoding BRCA1-associated protein 1 (BAP1) in more than 80%
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of metastasising tumors, implicating a role in the progression of uveal melanoma. [19] Mutations in
SF3B1 and EIF1AX in primary uveal melanoma are associated with a relatively good prognosis. [20,21]
Greater understanding of the molecular pathogenesis may provide opportunities for patients who
benefit from surveillance and may eventually provide specific targeted therapy for metastatic uveal
melanoma patients.
Over the past few years, different treatment strategies have been evaluated in patients with
metastatic uveal melanoma. The best responses have been reported with local treatment strategies
in patients with exclusive and limited hepatic metastasis in whom surgical resection, isolated
hepatic perfusion with melphalan, radiotherapy, radiofrequency ablation or radio-embolization
was performed [10–15]. In patients with diffuse liver metastases or extensive extrahepatic metastases,
systemic therapy is the only treatment strategy available. Several combinations of drugs have been
investigated in phase Ib/II/III trials in patients with metastatic uveal melanoma. Until now, none of the
systemic treatments with chemotherapy, [22–24] immune checkpoint inhibitors [25–32] or targeted
therapy, [33,34] have shown substantial efficacy in metastatic uveal melanoma.
In this article, we present data from our Dutch cohort of metastatic uveal melanoma patients
describing affected metastatic sites, mutation analysis, clinical characteristics associated with survival
and treatment choices made and the corresponding one-year survival. By describing these groups
of patients, we show the impact of clinical characteristics and selecting metastatic UM patients for
treatment in our real-life population.
2. Results
2.1. Patient Characteristics
Of the 3959 registered patients in the DMTR, a total of 175 metastatic uveal melanoma patients
were identified for analysis (Figure 1). Baseline characteristics are presented in Table 1.
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Table 1. Patient characteristics at the moment of diagnosis with metastatic disease.
Patient Characteristics All Patients(n = 175)
Systemic Therapy
(n = 67)
Local Therapy
(n = 39)
Best Supportive Care
(n = 69) p-Value
Age 0.001
Median, years (range) 65 (29–89) 61 (29–80) 61 (41–80) 69 (45–89)
<65 years (%) 86 (49.1) 39 (58.2) 25 (64.1) 22 (31.9)
>65 years (%) 89 (50.9) 28 (41.8) 14 (35.9) 47 (68.1)
Gender (%) 0.98
Male 88 (50.3) 34 (50.7) 20 (51.3) 34 (49.3)
Female 87 (49.7) 33 (49.3) 19 (48.7) 35 (50.7)
WHO performance score (%) 0.000
0 106 (60.6) 55 (82.1) 21 (53.8) 30 (60.6)
1 25 (14.3) 7 (10.4) 3 (7.7) 15 (21.7)
2 11 (6.3) 2 (3) 1 (2.6) 8 (11.6)
3 3 (1.7) 0 0 3 (4.3)
4 1 (0.6) 0 0 1 (1.4)
Unknown 29 (16.6) 3 (4,5) 14 (35,9) 12 (17.4)
Median time from diagnosis primary tumor to stage IV 0.02 *
months (range) 38 (0–477) 43 (0–296) 29 (0–477) 42 (0–361)
Brain metastases (%) 0.75
No 169 (96.6) 64 (95.5) 39 (100) 66 (95.7)
Yes 3 (1.7) 2 (3) 0 1 (1.4)
Unknown 3 (1.7) 1 (1.5) 0 2 (2.9)
Liver metastases (%) 0.10
No 20 (11.4) 11 (16.4) 1 (2.6) 8 (11.6)
Yes 154 (88) 56 (83.6) 38 (97.4) 60 (87)
Unknown 1 (0.6) 0 0 1 (1.4)
Metastatic sites (%) 0.002
<3 metastatic sites 134 (76.6) 44 (65.7) 39 (100) 52 (75.4)
>3 metastatic sites 31 (17.7) 18 (26.9) 0 13 (18.8)
Unknown 10 (5.7) 5 (7.5) 0 4 (5.8)
LDH (%) 0.000
Not elevated 81 (46.3) 37 (55.2) 26 (66.7) 18 (26.1)
Elevated (250–500) 34 (19.4) 12 (17.9) 9 (23.1) 13 (18.8)
Elevated (>500) 51 (29.1) 17 (25.4) 1 (2.6) 33 (47.8)
Unknown 9 (5.1) 1 (1.5) 3 (7.7) 5 (7.2)
* A rank-sum test for the median time from diagnosis to stage IV disease was used to test the difference between groups of patients. WHO performance score: World-Health Organization
performance score. LDH: lactate dehydrogenase.
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The median age of metastatic UM patients in this cohort was 65 years. The majority of patients
(74.9%) scored well on the World Health Organization (WHO) performance scale (0–1). Lactate
dehydrogenase level (LDH) was elevated in 85 (48.6%) patients (Table 1). The liver was the most
affected site: 88% of patients having liver metastases. Other affected sites were the lungs (25.1%),
lymph nodes (16%) and bones (15.4%) (Figure 2). Differences in clinical characteristics between the
treatment groups are presented in Table 1.Cancers 2019, 11, x 5 of 14 
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2.2. Mutation Analysis
Molecular analysis of the activating mutation in the GNAQ or GNA11 genes was performed in 63
patients (36%) (Figure 3). The fact that detection f these mutation was of no therapeutic consequence
might explain why thes genes w re not included in a standard NGS panel. I 31 of these 63 (49.2%)
patients a utation in the GNAQ was discovered and in 18 patients (28.6%) a GNA11 mutation was
confirmed. These results are consistent with the known literature describing most primary uveal
melanoma having a GNAQ or GNA11 mutation [18,35].
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2.3. Treatment of Metastatic UM Patients
In our study, 67 patients (38.3%) received systemic therapy when diagnosed with metastatic
disease. Several systemic drug regimens were applied, both in- and outside a clinical trial setting as
there is no standard of care for patients with metastatic uveal melanoma. These regimens consisted of
chemotherapy with dacarbazine, immune checkpoint inhibitors or targeted drugs. Several different
clinical trials, varying from phase I to phase III trials, were open for patient enrollment at different time
windows in the investigated period. All patients receiving a targeted drug participated in a clinical
trial; for example, in the NCT01430416 trial (phase 1 trial with AEB071), NCT01801358 trial (phase 1b/II
study with AEB071 + MEK162), NCT01974752 trial (phase 3 trial with selumetinib, or NCT02601378
(phase 1 trial with LXS196). In addition, patients could be included into the N11RFA trial, a phase
II study exploring the combination of ipilimumab with RFA. Fifty-three (79.1%) of 67 patients were
treated in a clinical trial as a part of first-line systemic therapy. Some patients received more than one
treatment after the failure of first-line therapy. During registration, a total of 108 systemic therapies
were given, in total 85 (78.7%) of these treatments were part of participation in a clinical trial (Figure 4).
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Figure 4. Treatment strategies per treatment episode. So e patients received more than one line of
treatment after failure of first-line treatment. (treatment episode 1: treatment strategy performed when
diagnosed with metastatic uveal melanoma, treatment episode 2: second treatment strategy after failure
of first-line treatment etc.).
Sixteen patients received systemic treatment with a checkpoint inhibitor outside a clinical trial
setting. Four patients received the anti-CTLA-4 antibody ipilimumab and 12 patients received an
anti-PD1 antibody One patient was treated with the combination of anti-CTLA-4 and nti-PD1 th rapy.
As most patients treated w th anti-CTLA-4 antibody were included in a clinic l tr al (as part of a ph se II
study expl ring the combination of ipilimumab with RFA, EudraCT Number: 2011-004200-38), overall
survival data for this group are not yet available. The median OS of these 12 patients treated with an
anti-PD1 antibody was 54.3 weeks, ranging between 6 and 104 weeks. Data on duration of treatment,
best overall response and overall survival are shown in Figure 5. Median follow-up computed with
reverse Kaplan- Meier was equal to 89 weeks (95% CI 70.76–107.24).
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Figure 5. Best response and survival of 12 metastatic UM patients treated with an anti-PD1 antibody
(no clinical trial participation).
Thirty-nine patients (22.3%) received local treatment when first diagnosed with metastatic uveal
melanoma. These local treatment regimens included surgical resection of metastases, isolated hepatic
perfusion with melphalan, radiothera y, radiofrequency ablation or radio-embolization. Sixty-nine
patients (39.4%) did not receive anti-tumor directed therapy but received best supportive care (Figure 1).
2.4. Survival
The median follow-up was computed with reverse Kaplan-Meier (where the event indicator is
reversed so that the outcome of interest is censored [36] and was equal to 120 weeks (95% CI 96.3–143.7).
One year after the diagnosis of metastatic uveal melanoma, 47.8% of all patients were alive (95% CI
40.4–55.2). There is a considerable difference in survival at one year among patients belonging to
different treatment groups and patients included in the BSC-group. The prognosis at one-year observed
in patients receiving systemic therapy or local therapy was 49% (95% CI 37–61) and 82.1% (95% CI
70.1–94.1), respectively. One-year survival for patients receiving best supportive care was equal to
27.5% (95% CI 16.9–38.1) (Figure 6).
The multivariable Cox analysis showed that slight to moderately elevated LDH (250–500 U/L)
and high LDH level (>500 U/L) were a statistically significant factor associated with poor survival
(p < 0.001), HR of 1.8 (95% CI 1.07–3.01) and 9.0 (95% CI 5.63–14.35) respectively. Also, the presence
of liver metastases was negatively associated with survival, HR 2.09 (95% CI 1.07–4.08, p = 0.03).
A WHO performance score >1 on its own seemed to be associated with poorer survival in a univariable
Cox analysis. However, when included in the multivariable analysis this association was no longer
statistically significant. “Age” as a continuous variable was included in the model, but was not
statistically significant (HR 1.0 (95% CI 0.99–1.02), p = 0.69). (Figure 7).
Figure S1 shows Kaplan-Meier estimates for survival when patients are categorized according to
non-elevated versus elevated serum LDH for all three treatment groups at baseline. Both in the group
of patients not receiving tumor-directed treatment (BSC) and the systemically treated group, an LDH
above 250 U/l was clearly associated with poorer survival (p < 0.001). However, in the local treatment
group, this difference was not statistically significant (p = 0.15).
Cancers 2019, 11, 1007 8 of 13
Cancers 2019, 11, x 7 of 14 
 
 
Figure 5. Best response and survival of 12 metastatic UM patients treated with an anti-PD1 antibody 
(no clinical trial participation). 
2.3. Survival 
The median follow-up was computed with reverse Kaplan-Meier (where the event indicator is 
reversed so that the outcome of interest is censored [36] and was equal to 120 weeks (95% CI 96.3–
143.7). One year after the diagnosis of metastatic uveal melanoma, 47.8% of all patients were alive 
(95% CI 40.4–55.2). There is a considerable difference in survival at one year among patients 
belonging to different treatment groups and patients included in the BSC-group. The prognosis at 
one-year observed in patients receiving systemic therapy or local therapy was 49% (95% CI 37–61) 
and 82.1% (95% CI 70.1–94.1), respectively. One-year survival for patients receiving best supportive 
care was equal to 27.5% (95% CI 16.9–38.1) (Figure 6). 
 
(A) (B) 
Cancers 2019, 11, x 8 of 14 
 
(C) (D) 
Figure 6. Kaplan-Meier Estimates for all 175 metastatic UM patients and per treatment strategy 
administered when diagnosed with metastatic disease. (A) Kaplan-Meier (KM) estimate for all 
metastatic UM patients, (B) KM estimate for patients treated with systemic therapy, (C) KM estimate 
for patients with local treatment, (D) KM estimate for patients receiving no tumor directed treatment 
(best supportive care. 
The multivariable Cox analysis showed that slight to moderately elevated LDH (250–500 U/L) 
and high LDH level (>500 U/L) were a statistically significant factor associated with poor survival (p 
< 0.001), HR of 1.8 (95% CI 1.07–3.01) and 9.0 (95% CI 5.63–14.35) respectively. Also, the presence of 
liver metastases was negatively associated with survival, HR 2.09 (95% CI 1.07–4.08, p = 0.03). A WHO 
performance score >1 on its own seemed to be associated with poorer survival in a univariable Cox 
analysis. However, when included in the multivariable analysis this association was no longer 
statistically significant. “Age” as a continuous variable was included in the model, but was not 
statistically significant (HR 1.0 (95% CI 0.99–1.02), p = 0.69). (Figure 7). 
Figure S1 shows Kaplan-Meier estimates for survival when patients are categorized according 
to non-elevated versus elevated serum LDH for all three treatment groups at baseline. Both in the 
group of patients not receiving tumor-directed treatment (BSC) and the systemically treated group, 
an LDH above 250 U/l was clearly associated with poorer survival (p < 0.001). However, in the local 
treatment group, this difference was not statistically significant (p = 0.15). 
 
Figure 7. Multivariable hazard ratios (HR) associated with poorer survival in the full cohort along 
with the 95% confidence interval (CI).  
Figure 6. Kaplan-Meier Estimates for all 175 metastatic UM patients and per treatment strategy
administered when diagnosed with metastatic disease. (A) Kaplan-Meier (KM) estimate for all metastatic
UM patients, (B) KM estimate for patients treated with systemic therapy, (C) KM estimate for patients with
local treatment, (D) KM estimate for patients receiving no tumor directed treatment (best supportive care.
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3. Discussion
Metastatic uveal melanoma has a poor prognosis, usually leading to rapid clinical decline and
early death. According to the literature, the majority of patients survive for less than 12 months [7,8].
In our cohort, we analysed 175 patients with metastatic uveal melanoma according to first-line treatment
strategies administered when they were diagnosed with stage IV disease between July 2012 and March
2018. The real-world results of this observational cohort are a reflection of uveal melanoma care available
in the Netherlands and this article does not compare different treatment strategies and/or the impact on
patient outcome. In our cohort, one-year survival for all patients with metastatic uveal melanoma is
equal to 47.8% (95% CI 40.4–55.2), similar to that reported in known publications [7,8]. Studies reporting
on survival in metastatic uveal melanoma have found the best results in terms of survival among patients
in whom surgery or ablative procedures can be performed and among patients with solitary hepatic
metastases [10–15]. Overall, these findings are suggestive of survival benefit, although it is likely that
there is a selection bias towards the most clinically fit patients [9]. Based on the results in literature,
the first choice of treatment in the Netherlands is, whenever possible, surgery, ablative procedures or
isolated hepatic perfusion with melphalan (in a clinical trial setting). In line with the literature, our
cohort shows a selection of relatively younger patients, with good WHO performance score, fewer
metastatic sites and less elevated LDH who were treated with local treatment options. As no systemic
therapy has been shown to improve overall survival for patients with metastatic uveal melanoma, there
is no specific standard of care and patients should be directed to clinical trials. In the Netherlands,
metastatic melanoma care has been centralised to 14 expert centers [36] improving management of
metastatic melanoma patients, but also facilitating enrollment in clinical trials to get evidence-based
treatment protocols. In our cohort in total 85 systemic therapies were given in the context of a clinical
trial, to 63 unique patients. The lack of availability of clinical trials was sometimes a reason to provide
systemic therapy outside a clinical trial setting. These systemic therapies were registered for treatment of
metastatic cutaneous melanoma and given to patients with metastatic uveal melanoma. In the present
situation, decision making on available treatment options in metastatic UM patients occurs mainly
on clinical characteristics leading to selection of patients for treatment in- and outside a clinical trial.
The limited efficacy of checkpoint inhibitors in uveal melanoma has led to the agreement among members
of the Dutch Working Group on immunotherapy and oncology (WIN-O) not to treat patients with
immune checkpoint inhibitors outside a clinical trial. Combination studies on ipilimumab/nivolumab
and novel immune-based approaches might be more promising [37].
In our cohort of UM patients, classic risk factors associated with survival, as elevated LDH
and the presence of liver metastases [7,8] are confirmed to be negatively associated with survival
(Figure 7). The distribution of metastases (Figure 2) in our cohort is consistent with data from the large
Collaborative Ocular Melanoma Study trials [38].
Our observational cohort may suffer from limitations in terms of the registration of real-world
data, sometimes leading to missing variables which might affect results, especially in smaller treatment
groups. For instance, in the group of patients receiving local treatment (39 patients) information on
WHO performance score was missing in 14 patients (35.9%). Another registration flaw was detected
in the documentation of the molecular analysis, reporting a GNAQ and GNA11 mutation in 6.4% of
the analysed patients. These mutations are mutually exclusive. Other limitations relate to the choice
of data to collect in a registry. From a scientific perspective, a broad set of clinical and pathological
characteristics (including molecular and genomic alterations), treatment strategies, adverse events
and survival is desirable. This is, however, not always feasible, and ongoing developments are more
difficult to incorporate. At this time, the DMTR contains limited data on molecular and genomic
tumor alterations.
Important strengths of our observational cohort are the complete overview of patient and
metastatic tumor characteristics and treatment options available in the Netherlands between 2012 and
2018 for metastatic uveal melanoma patients. Differences in metastatic UM patients are most probably
caused by differences in baseline characteristics and patient selection for specific treatment. However,
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this overview might be used by other authors for comparing survival between treatment groups and
the impact of their treatment strategy applied.
4. Patients and Methods
4.1. Datasource
Since 2013, all Dutch metastatic melanoma patients have been referred to one of the 14 melanoma
expert centers in the Netherlands. This centralisation of metastatic melanoma patients and the
registration in the Dutch Melanoma Treatment Registry (DMTR), (providing nation-wide coverage
retrospectively starting from July 2012), was initiated to assure safety and quality of melanoma care
in the Netherlands [36]. Since the DMTR was set up, all patients with metastatic melanoma have
been included in the registry, irrespective of the type of primary melanoma (i.e., cutaneous, uveal, or
mucosal melanoma). The DMTR provides aggregated data information on basic patient and tumor
characteristics, treatment regimens, grade 3 and 4 treatment related adverse events (according to the
Common Terminology Criteria for Adverse Events, version 4.0) and clinical outcomes.
In compliance with Dutch regulations, the DMTR was approved by a medical ethical committee
(METC Leiden University Medical Centre, 3 September 2013) and is not considered subject to the
Medical Research Involving Human Subjects Act. All data are collected anonymously and only
aggregated data are available for research and quality improvements. Data extraction from medical
files is performed by data-employees. No informed consent will be signed, but patients are offered
an opt-out possibility if they do not want their data registered in the DMTR. For this study, the data
cut-off date was 25th March 2018.
4.2. Patients
Between July 2012 and March 2018, 227 patients with metastatic uveal melanoma were registered
in the DMTR. Patients who received treatment before the DMTR was set up were excluded from
analysis (Figure 1). We analysed 175 treatment-naive patients according to the type of treatment
initiated at first presentation with metastatic disease: i.e., patients could be receiving: (i) systemic
therapy, (ii) local treatment, or (iii) no tumor-directed therapy, but best supportive care (BSC). For this
manuscript, we analysed only patients who had their first treatment post July 2012.
Systemic therapy included a variety of regimens with chemotherapy, immune checkpoint inhibitors
and targeted drugs. Local treatment strategies included surgical resection, isolated hepatic perfusion
with melphalan, radiotherapy, radiofrequency ablation or immune-embolization. Treatment strategies
were performed either as standard care or in the context of participation in a clinical trial.
4.3. Statistical Analysis
Descriptive statistics were employed to summarise patient baseline characteristics on registration
in the DMTR. To test the difference between categorical variables for different treatment strategy
groups, a chi-square test was applied (Table 1). A rank-sum test has been used to test the difference
between the median time from diagnosis to stage IV disease between groups of patients. Survival
from the diagnosis of metastatic disease, was estimated according to Kaplan-Meier’s method. Median
follow up was computed with reverse Kaplan-Meier method [39].
A univariable Cox analysis using variables “age” (age as a continuous variable), “gender”
(male versus female), “WHO performance score” (WHO 0–1 vs. WHO ≥ 2), “LDH level” (elevated vs.
non-elevated LDH) and the “presence of liver metastases” was performed. Subsequently, a multivariable
Cox regression model was estimated, including the variables known to influence survival in metastatic
cutaneous melanoma patients. All statistical analyses were conducted using SPSS (SPSS, version 23,
IBM Corp. released 2015, Armonk, NY, USA).
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5. Conclusions
We present baseline characteristics, mutation analysis and treatment strategies with the
corresponding one-year survival of a nation-wide (full coverage) cohort of 175 patients with metastatic
uveal melanoma in the Netherlands. Selection of patients for treatment was mainly based on clinical
characteristics, showing elevated LDH (HR 9.0, 95% CI 5.63–14.35), and the presence of liver metastases
(HR 2.09, 95% CI. 1.07–4.08) was negatively associated with survival in metastatic UM. The analysis of
our observational cohort reflects the treatment choices made by physicians in Dutch melanoma expert
centers. Our overview might be used by other authors for comparing survival between treatment
groups and the impact of treatment strategy applied.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/7/1007/s1,
Figure S1: Kaplan-Meier Estimates per treatment strategy and level of LDH (normal LDH < 250 U/L vs. elevated
LDH > 250 U/L).
Author Contributions: Conceptualization, A.J., M.K.v.d.K., M.F., M.G.S., M.J.A., A.C.v.A., F.W.P.J.v.d.B.,
A.J.M.v.d.E., M.G.F., J.W.B.d.G., J.B.A.G.H., G.A.P.H., R.H.K., W.H.J.K., M.L., D.P., R.S.v.R., K.P.M.S., A.J.t.T., G.V.,
M.W.J.M.W., M.C.T.v.Z., K.J.M.v.d.H. and E.K.; Formal analysis, A.J., M.K.v.d.K., M.F., M.W.J.M.W., K.J.M.v.d.H.
and E.K.; Methodology, A.J., M.K.v.d.K., M.F., M.W.J.M.W., K.J.M.v.d.H. and E.K.; Visualization, A.J. and
M.K.v.d.K.; Writing—original draft, A.J. and M.K.v.d.K.; Writing—review & editing, M.F., M.G.S., M.J.A., A.C.v.A.,
F.W.P.J.v.d.B., C.U.B., A.J.M.v.d.E., M.G.F., J.W.B.d.G., J.B.A.G.H., G.A.P.H., R.H.K., W.H.J.S.v.R., K.P.M.S., A.J.t.T.,
G.V., M.W.J.M.W., M.C.T.v.Z., K.J.M.v.d.H. and E.K.
Funding: This specific research manuscript received no external funding. The Netherlands Organization for
Health Research and Development funded the start-up of the Dutch Melanoma Treatment Registry (DMTR). Grant
number: 836002002. This grant was awarded under the effectiveness research for high-cost medicine programme.
From its foundation, the DMTR was sponsored by BMS, GSK (later acquired by Novartis), Roche Nederland B.V.
and MSD (from 2015) via the Dutch Institute for Clinical Auditing (DICA).
Acknowledgments: The Dutch Melanoma Treatment Registry (DMTR) is facilitated by the Dutch Institute for
Clinical Auditing (DICA). Data entry was conducted by data employees trained and monitored by The Netherlands
Comprehensive Cancer Organisation (IKNL). All collected data were checked and verified by medical oncologists.
Conflicts of Interest: In relation to their contribution to this specific manuscript the authors declare no conflict
of interest. Some authors however have consulting/advisory relationships and have received funding for other
research projects. A.J. has in the past received travel/ accommodation expenses from Roche BV Netherlands.
A.C.v.A. has consulting/advisory relationships with Amgen, BMS, Novartis, MSD and Merck-Pfizer. He has
received research funding from Amgen and Novartis and travel, accommodations, and expenses from Amgen and
Novartis. C.U.B. has consulting/advisory relationships with BMS, MSD, Roche, Novartis, GSK, Lilly and Pfizer.
He has received research funding from Novartis. A.J.M.v.d.E. has consulting/advisory relationships with BMS,
Roche, MSD and Novartis. He has received a study grant from R. MargreetG. Franken has received grants from
Roche BV Netherlands, Daiichi Sanky, AbbVie, Pamgene and Gilead Sciences. Jan Willem B. de Groot has advisory
relationships with BMS, MSD and Roche. J.B.A.G. Haanen has provided consultation, attended advisory boards,
and/or provided lectures for MSD, BMS, Roche and Novartis for which NKI received honoraria. His institution
has received grant support from BMS and Novartis. G.A.P.H. has consulting/advisory relationships with Roche,
MSD, BMS and Novartis. Her institution has received research funding from BMS. RutgerH. Koornstra has
received speaker fees from BMS, MSD and Roche. He has advisory relationships with BMS, MSD, Novartis and
Roche and has received research grants from BMS and Roche. K.P.M.S. has consulting/advisory relationships with
BMS and MSD and has received honoraria from Novartis, Roche and Pierre Fabre (paid to institution). E.K. has
consulting/advisory relationships with BMS, Novartis, Roche, Amgen, Pierre Fabre (honoraria paid to institution)
and has received research grants from BMS, Novartis.
References
1. Bedikian, A.Y. Metastatic uveal melanoma therapy: Current options. Int. Ophthalmol. Clin. 2006, 46, 151–166.
[CrossRef]
2. Damato, B. Treatment of primary intraocular melanoma. Expert Rev. Anticancer Ther. 2006, 6, 493–506. [CrossRef]
3. Dutch Cancer Registry. Available online: https://www.cijfersoverkanker.nl/ (accessed on 12 December 2018).
4. Mallone, S.; De Vries, E.; Guzzo, M.; Midena, E.; Verne, J.; Coebergh, J.W.; Marcos-Gragera, R.; Ardanaz, E.;
Martinez, R.; Chirlaque, M.D.; et al. Descriptive epidemiology of malignant mucosal and uveal melanomas
and adnexal skin carcinomas in Europe. Eur. J. Cancer 2012, 48, 1167–1175. [CrossRef] [PubMed]
5. Spagnolo, F.; Caltabiano, G.; Queirolo, P. Uveal melanoma. Cancer Treat. Rev. 2012, 38, 549–553. [CrossRef]
[PubMed]
Cancers 2019, 11, 1007 12 of 13
6. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy
for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28.
Arch. Ophthalmol. 2006, 124, 1684–1693. [CrossRef] [PubMed]
7. Kujala, E.; Makitie, T.; Kivela, T. Very long-term prognosis of patients with malignant uveal melanoma.
Investig. Ophthalmol. Vis. Sci. 2003, 44, 4651–4659. [CrossRef] [PubMed]
8. Rietschel, P.; Panageas, K.S.; Hanlon, C.; Patel, A.; Abramson, D.H.; Chapman, P.B. Variates of survival in
metastatic uveal melanoma. J. Clin. Oncol. 2005, 23, 8076–8080. [CrossRef]
9. Augsburger, J.J.; Correa, Z.M.; Shaikh, A.H. Effectiveness of treatments for metastatic uveal melanoma.
Am. J. Ophthalmol. 2009, 148, 119–127. [CrossRef] [PubMed]
10. Hughes, M.S.; Zager, J.; Faries, M.; Alexander, H.R.; Royal, R.E.; Wood, B.; Choi, J.; McCluskey, K.; Whitman, E.;
Agarwala, S.; et al. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic
Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. Ann. Surg. Oncol.
2016, 23, 1309–1319. [CrossRef]
11. Stinauer, M.A.; Kavanagh, B.D.; Schefter, T.E.; Gonzalez, R.; Flaig, T.; Lewis, K.; Robinson, W.; Chidel, M.;
Glode, M.; Raben, D. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: Impact of
single fraction equivalent dose on local control. Radiat. Oncol. 2011, 6, 34. [CrossRef]
12. Shashank, A.; Shehata, M.; Morris, D.L.; Thompson, J.F. Radiofrequency ablation in metastatic melanoma.
J. Surg. Oncol. 2014, 109, 366–369. [CrossRef]
13. Huppert, P.E.; Fierlbeck, G.; Pereira, P.; Schanz, S.; Duda, S.H.; Wietholtz, H.; Rozeik, C.; Claussen, C.D.
Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur. J. Radiol. 2010,
74, e38–e44. [CrossRef]
14. Pawlik, T.M.; Zorzi, D.; Abdalla, E.K.; Clary, B.M.; Gershenwald, J.E.; Ross, M.I.; Aloia, T.A.; Curley, S.A.;
Camacho, L.H.; Capussotti, L.; et al. Hepatic resection for metastatic melanoma: Distinct patterns of recurrence
and prognosis for ocular versus cutaneous disease. Ann. Surg. Oncol. 2006, 13, 712–720. [CrossRef]
15. De Leede, E.M.; Burgmans, M.C.; Kapiteijn, E.; Luyten, G.P.; Jager, M.J.; Tijl, F.G.; Hartgrink, H.H.;
Grunhagen, D.J.; Rothbarth, J.; van de Velde, C.J.; et al. Isolated (hypoxic) hepatic perfusion with high-dose
chemotherapy in patients with unresectable liver metastases of uveal melanoma: Results from two experienced
centres. Melanoma Res. 2016, 26, 588–594. [CrossRef]
16. Nathan, P.; Cohen, V.; Coupland, S.; Curtis, K.; Damato, B.; Evans, J.; Fenwick, S.; Kirkpatrick, L.; Li, O.;
Marshall, E.; et al. Uveal Melanoma UK National Guidelines. Eur. J. Cancer 2015, 51, 2404–2412. [CrossRef]
17. Melanoom, T. Available online: www.oncoline.nl/uveamelanoom (accessed on 12 December 2018).
18. Shoushtari, A.N.; Carvajal, R.D. GNAQ and GNA11 mutations in uveal melanoma. Melanoma Res. 2014, 24,
525–534. [CrossRef]
19. Harbour, J.W.; Onken, M.D.; Roberson, E.D.; Duan, S.; Cao, L.; Worley, L.A.; Council, M.L.; Matatall, K.A.;
Helms, C.; Bowcock, A.M. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330,
1410–1413. [CrossRef]
20. Martin, M.; Masshofer, L.; Temming, P.; Rahmann, S.; Metz, C.; Bornfeld, N.; van de Nes, J.; Klein-Hitpass, L.;
Hinnebusch, A.G.; Horsthemke, B.; et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX
and SF3B1 in uveal melanoma with disomy 3. Nat. Genet. 2013, 45, 933–936. [CrossRef]
21. Yavuzyigitoglu, S.; Koopmans, A.E.; Verdijk, R.M.; Vaarwater, J.; Eussen, B.; van Bodegom, A.; Paridaens, D.;
Kilic, E.; de Klein, A.; Rotterdam Ocular Melanoma Study Group. Uveal Melanomas with SF3B1 Mutations:
A Distinct Subclass Associated with Late-Onset Metastases. Ophthalmology 2016, 123, 1118–1128. [CrossRef]
22. Flaherty, L.E.; Unger, J.M.; Liu, P.Y.; Mertens, W.C.; Sondak, V.K. Metastatic melanoma from intraocular
primary tumors: The Southwest Oncology Group experience in phase II advanced melanoma clinical trials.
Am. J. Clin. Oncol. 1998, 21, 568–572. [CrossRef]
23. Nathan, F.E.; Berd, D.; Sato, T.; Shield, J.A.; Shields, C.L.; De Potter, P.; Mastrangelo, M.J. BOLD+ interferon
in the treatment of metastatic uveal melanoma: First report of active systemic therapy. J. Exp. Clin. Cancer
Res. CR 1997, 16, 201–208.
24. Kivela, T.; Suciu, S.; Hansson, J.; Kruit, W.H.; Vuoristo, M.S.; Kloke, O.; Gore, M.; Hahka-Kemppinen, M.;
Parvinen, L.M.; Kumpulainen, E.; et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in
combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur. J. Cancer 2003, 39,
1115–1120. [CrossRef]
Cancers 2019, 11, 1007 13 of 13
25. Kelderman, S.; van der Kooij, M.K.; van den Eertwegh, A.J.; Soetekouw, P.M.; Jansen, R.L.; van den Brom, R.R.;
Hospers, G.A.; Haanen, J.B.; Kapiteijn, E.; Blank, C.U. Ipilimumab in pretreated metastastic uveal melanoma
patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol. 2013,
52, 1786–1788. [CrossRef]
26. Zimmer, L.; Vaubel, J.; Mohr, P.; Hauschild, A.; Utikal, J.; Simon, J.; Garbe, C.; Herbst, R.; Enk, A.; Kampgen, E.;
et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal
melanoma. PLoS ONE 2015, 10, e0118564. [CrossRef]
27. Maio, M.; Danielli, R.; Chiarion-Sileni, V.; Pigozzo, J.; Parmiani, G.; Ridolfi, R.; De Rosa, F.; Del Vecchio, M.;
Di Guardo, L.; Queirolo, P.; et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal
melanoma. Ann. Oncol. 2013, 24, 2911–2915. [CrossRef]
28. Kottschade, L.A.; McWilliams, R.R.; Markovic, S.N.; Block, M.S.; Villasboas Bisneto, J.; Pham, A.Q.; Esplin, B.L.;
Dronca, R.S. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 2016,
26, 300–303. [CrossRef]
29. Bender, C.; Enk, A.; Gutzmer, R.; Hassel, J.C. Anti-PD-1 antibodies in metastatic uveal melanoma: A treatment
option? Cancer Med. 2017, 6, 1581–1586. [CrossRef]
30. Algazi, A.P.; Tsai, K.K.; Shoushtari, A.N.; Munhoz, R.R.; Eroglu, Z.; Piulats, J.M.; Ott, P.A.; Johnson, D.B.;
Hwang, J.; Daud, A.I.; et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1
antibodies. Cancer 2016, 122, 3344–3353. [CrossRef]
31. Heppt, M.V.; Heinzerling, L.; Kahler, K.C.; Forschner, A.; Kirchberger, M.C.; Loquai, C.; Meissner, M.; Meier, F.;
Terheyden, P.; Schell, B.; et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with
programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur. J. Cancer 2017,
82, 56–65. [CrossRef]
32. van der Kooij, M.K.; Joosse, A.; Speetjens, F.M.; Hospers, G.A.; Bisschop, C.; de Groot, J.W.; Koornstra, R.;
Blank, C.U.; Kapiteijn, E. Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands. Acta Oncol.
2017, 56, 101–103. [CrossRef]
33. Carvajal, R.D.; Sosman, J.A.; Quevedo, J.F.; Milhem, M.M.; Joshua, A.M.; Kudchadkar, R.R.; Linette, G.P.;
Gajewski, T.F.; Lutzky, J.; Lawson, D.H.; et al. Effect of selumetinib vs chemotherapy on progression-free
survival in uveal melanoma: A randomized clinical trial. JAMA 2014, 311, 2397–2405. [CrossRef]
34. Carvajal, R.D.; Piperno-Neumann, S.; Kapiteijn, E.; Chapman, P.B.; Frank, S.; Joshua, A.M.; Piulats, J.M.;
Wolter, P.; Cocquyt, V.; Chmielowski, B.; et al. Selumetinib in Combination With Dacarbazine in Patients
With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). J. Clin. Oncol. 2018,
36, 1232–1239. [CrossRef]
35. Van Raamsdonk, C.D.; Griewank, K.G.; Crosby, M.B.; Garrido, M.C.; Vemula, S.; Wiesner, T.; Obenauf, A.C.;
Wackernagel, W.; Green, G.; Bouvier, N.; et al. Mutations in GNA11 in uveal melanoma. N. Engl. J. Med.
2010, 363, 2191–2199. [CrossRef]
36. Jochems, A.; Schouwenburg, M.G.; Leeneman, B.; Franken, M.G.; van den Eertwegh, A.J.; Haanen, J.B.;
Gelderblom, H.; Uyl-de Groot, C.A.; Aarts, M.J.; van den Berkmortel, F.W.; et al. Dutch Melanoma
Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.
Eur. J. Cancer 2017, 72, 156–165. [CrossRef]
37. Pelster, M.; Gruschkus, S.K.; Basset, R.; Gombus, D.S.; Shephard, M.; Posada, L.; Glover, M.; Diab, A.;
Hwu, P.; Patel, S.P. Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma
(UM). J. Clin. Oncol. 2019, 37, 9522. [CrossRef]
38. Diener-West, M.; Reynolds, S.M.; Agugliaro, D.J.; Caldwell, R.; Cumming, K.; Earle, J.D.; Hawkins, B.S.;
Hayman, J.A.; Jaiyesimi, I.; Jampol, L.M.; et al. Development of metastatic disease after enrollment in the
COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No.
26. Arch. Ophthalmol. 2005, 123, 1639–1643. [CrossRef]
39. Schemper, M.; Smith, T.L. A note on quantifying follow-up in studies of failure time. Control. Clin. Trials
1996, 17, 343–346. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
